A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel vs. placebo + Trastuzumab + Docetaxel in patients with previously untreated HER2-positive metastatic b